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Abstract
Background: Activation of microglia is a part of the inflammatory response in neurodegenerative
diseases but its role in the pathophysiology of these diseases is still unclear. The osteopetrotic (op/
op) mouse lacks colony-stimulating factor-1 (CSF-1) and thus has a deficiency in microglia and
macrophages. Prior reports have demonstrated that op/op mice deposit amyloid β (Aβ) plaques,
similar to those found in Alzheimer's disease. The purpose of these studies was to confirm this and
to determine if the lack of CSF-1 affects the development of dopaminergic neurons and the
expression of CD200, a known microglial inhibitory protein.
Method: We examined the central nervous system of op/op mice at 30 days, 60 days and 7 months
of age and wildtype littermates at 30 days using immunohistochemistry and histochemistry.
Results: We found a decrease in the number of microglia in 1 month-old op/op mice compared
to wildtype (WT) littermates as measured by CD11b, CD45, CD32/16, CD68, CD204 and F4/80
immunoreactivity. Aβ plaques were not detected, while the number of dopaminergic neurons
appeared normal. The expression of CD200 appeared to be normal, but there appeared to be a
lower expression in the substantia nigra.
Conclusion: In contrast to a prior report we did not detect Aβ deposition in the central nervous
system of op/op mice at 30 days, 60 days or 7 months of age and there was a normal number of
dopaminergic neurons. This indicates that op/op mice may be useful to examine the effects of
microglia on neurodegenerative disease progression by breeding them to different transgenic
mouse models. In addition, the lack of CSF-1 does not appear to affect CD200 expression by
neurons but we did note a decrease in the substantia nigra of op/op and WT mice, suggesting that
this may be a mechanism by which microglia control may be attenuated in this specific area during
Parkinson's disease.
1. Introduction
Alzheimer's disease (AD) and Parkinson's disease (PD)
affect an increasing number of people as the population
ages [1]. In AD brain, activated microglia are localized to
areas of β amyloid (Aβ) plaque [1,1-3], whilst in PD they
are found in the substantia nigra (SN), the site of
dopaminergic cell loss in PD [4,5]. In both AD and PD
there is epidemiological evidence [6,7] and animal model
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data [8,9] to suggest that suppressing inflammation is
beneficial. However, microglia activation can reduce Aβ
plaque development in AD mouse models [8,10,11] and
activated microglia secrete neurotrophic factors [8,12].
Thus the role of microglia during neurodegeneration is
complex. Alternative animal models may assist in address-
ing these difficult remaining questions.
Osteopetrotic (Csf1op/Csf1op or commonly called op/op)
mutant mice are deficient in colony stimulating factor-1
(CSF-1) due to a naturally occurring inactivating mutation
[13,14]. CSF-1, also known as macrophage colony stimu-
lating factor, has an important role in the proliferation
and differentiation of macrophages [15], subsequently
op/op mice are reported to have a deficiency in tissue
macrophages, including microglia [16]. However, this
deficiency may not be absolute, and the number of mac-
rophages appears to increase as the mice age [17]. If the
number of microglia is reduced op/op mice may be an
appropriate model to investigate the role of microglia and
astrocytes in neurodegenerative disease.
Microglia are the main immune type cell of the central
nervous system (CNS) and therefore are crucial to the
defense of the brain against invading micro-organisms,
tumors and following trauma. However, uncontrolled
activation may have deleterious outcomes. The mecha-
nisms by which the CNS accomplishes this balancing act
are slowly being elucidated but are known to include
astrocytes, neurons and microglia themselves. Some of
the mechanisms include the production of soluble factors
such as neurotrophins, cytokines and ligands such as
CD200 and its receptor CD200R and CD22 plus its recep-
tor CD45 [18,19]. It is unknown if the absence of micro-
glia will affect the appearance of these downregulatory
mechanisms.
The purpose of these experiments was to determine the
presence of microglia/macrophages in the CNS of op/op
mice using a panel of antibodies and if the reduced den-
sity of microglia affected the appearance of the downreg-
ulatory protein CD200 on neurons. In addition, we
examined whether the lack of CSF-1 and microglia




Breeding pairs of Csf1+/op mice (B6C3Fe genetic back-
ground) were purchased from the Jackson Laboratory (Bar
Harbor, ME) and bred at the School of Veterinary Medi-
cine, University of Wisconsin-Madison. Homozygous op/
op mice, identified by the lack of incisors around postna-
tal day 12, were fed with powdered rodent chow (Harlan,
Indianapolis, IN) and liquid rodent diet (Research Diets
Inc., New Brunswick, NJ) after weaning. The heterozygous
or WT littermates, as identified by the normal appearance
of teeth, were used as controls. All animal procedures were
approved by the University's Animal Care and Use Com-
mittee.
2.2 Tissue collection
At 30 days, 60 days and 7 months of age op/op mice and
30 day-old WT littermates (n = 3, each group) were deeply
anaesthetized and perfused with saline followed by 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4).
The brain was removed and placed in 4% paraformalde-
hyde for 8–10 hours, sucrose protected, embedded in
OCT (Sakura, Tokyo, Japan), and frozen in a dry ice
cooled isopentane bath. Tissue was then stored at -80°C
until use.
2.3 Immunohistochemistry, histochemistry and image 
analysis
Eight micron sections were cut using a cryostat, mounted
on glass slides and immunohistochemistry performed
using the ELITE ABC kit (Vector Laboratories, Burlingame,
CA) and diaminobenzidine as previously described [20].
The dilution and source of the utilized antibodies are
shown in Table 1.
Fibrillar Aβ was detected using 1% aqueous Thioflavin S
followed by differentiation in 3 changes of 80% ethanol
and examination by fluorescent microscopy. Congo red
staining was performed by immersing slides in a solution
of 0.1% Congo red solution for 5 minutes and differenti-
ation in a solution of 85% ethanol and 0.2% potassium
hydroxide. Slides were then examined using polarizing
microscopy and light microscopy.
Sections of spleen and brain from plaque-bearing 12
month-old J20 amyloid precursor protein (APP)-tg mice
[21] were included in all histochemistry and immunohis-
tochemistry experiments as positive controls. Negative
controls included sections incubated with normal IgG
from the same species as the primary antibody.
To quantify CD11b immunoreactivity, acquisition of
images was performed in a single session using a SPOT
camera (Sterling Heights, MI) using 3 equidistant (~100
μm) tissue sections. Computer assisted image analysis was
performed on images of hippocampus and SN using IP
Lab Spectrum 3.1 Image Analyzer (Fairfax, VA). The
threshold of detection was held constant during analysis.
Percent area occupied by CD11b immunoreactivity was
calculated for hippocampus and SN separately.
2.4 Data analysis
Using Prism software (GraphPad Software Inc., San
Diego, CA), statistical analysis was determined by theJournal of Neuroinflammation 2007, 4:31 http://www.jneuroinflammation.com/content/4/1/31
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Mann Whitney U test with a p value of < 0.05 considered
significant. All values reported include the average ± SEM.
3. Results
3.1 Microglia are significantly reduced in 30 day old op/op 
mice
Immunohistochemistry demonstrated a significant
decrease in CD11b expression in the hippocampus and
SN of 30 day-old op/op mice compared to WT littermates
(Figure 1 and 2). The majority of the residual CD11b-
expressing cells in the op/op CNS were ramified and
therefore can be tentatively identified as microglia. Immu-
nostaining with CD45 confirmed the reduced number of
microglia within the brain of op/op mice (Figure 3). Note
that the CD45 antibody labeled fewer cells in the hippoc-
ampus of wildtype mice as compared to the CD11b anti-
Expression of CD11b in the hippocampus and substantia nigra of 30-day-old op/op and WT mice Figure 1
Expression of CD11b in the hippocampus and substantia nigra of 30-day-old op/op and WT mice. Photomicrographs show 
that WT mice expressed CD11b in the hippocampus (A) with lower amounts detected in the substantia nigra (B). CD11b immunoreac-
tivity was lower in op/op mice in both the hippocampus (C) and substantia nigra (D) when compared to WT littermates. Scale bar – 100 
μm.
Table 1: Antibodies used for immunohistochemistry
Antigen (catalogue number) Antibody type Dilution Source
CD16/CD32 (553140) Rat monoclonal 1:2000 BD PharMingen (San Jose, CA)
CD11b (MCA711) Rat monoclonal 1:250 Serotec (Raleigh, NC)
CD45 (MCA 1031G) Rat monoclonal 1:5000 Serotec
CD68 (MCA 1957) Rat monoclonal 1:500 Serotec
CD204 (MCA 1322) Rat monoclonal 1:1000 Serotec
F4/80 (MCA497R) Rat monoclonal 1:250 Serotec
GFAP (Z 0334) Rabbit polyclonal 1:500 Dakocytomation (Carpinteria, CA)
DW14 (anti-Aβ) none Rabbit polyclonal 1:1000 Dr. Selkoe (Boston, MA)
R1282 (anti-Aβ) none Rabbit polyclonal 1:1000 Dr. Selkoe
Aβ 40 (44–348) Rabbit polyclonal 1:250 Biosource (Camarillo, CA)
Aβ 42 (44–344) Rabbit polyclonal 1:250 Biosource
tyrosine hydroxylase (AB152) Rabbit polyclonal 1:1000 Chemicon (Temecula, CA)
CD200 (552512) Rat monoclonal 1:250 BD PharMingen
MHC II (553621) rat monoclonal 1:500 BD PharMingenJournal of Neuroinflammation 2007, 4:31 http://www.jneuroinflammation.com/content/4/1/31
Page 4 of 9
(page number not for citation purposes)
body. Additionally CD32/16 (FcγIII/II), CD68 and F4/80
were all reduced in the CNS of the 30 day-old op/op mice
compared to WT littermates. We also examined the brains
for MHC II expression and found that both op/op and WT
mice expressed this marker only in cells located in the
choroid plexus (Figure 3). Based on their morphology and
position, the MCH II+ cells are likely macrophages in the
stroma of the choroid plexus. Therefore, it appears that
not all cells of the macrophage lineage are absent from the
brain.
There appeared to be an increase in the number of CD11b
and CD45 positive cells in the brains of op/op mice at 7
months of age, however WT littermates were not available
to perform a quantitative comparison.
Normal numbers of astrocyte, as detected using an anti-
GFAP antibody were found in op/op mice (data not
shown).
3.2 CD200 expression in op/op mice
CD200 is a widely expressed membrane protein contain-
ing 2 Ig superfamily domains, with its receptor expressed
on myeloid cells including microglia [22]. Using immu-
nohistochemistry we found no difference in the expres-
sion of CD200 in the hippocampus or SN of op/op mice
when compared to WT mice (Figure 4). As previously
reported CD200 protein was found on neuronal mem-
branes throughout the CNS, with some exceptions includ-
ing the neurons in the dentate gyrus and CA regions of the
hippocampus (Figure 4). Interestingly, there appeared to
be less neuronal expression of CD200 in the SN compared
to the hippocampus for both lines of mice.
3.3 Aβ plaques and dopaminergic neurons
We examined the CNS of 30 day, 60 day and 7 month-old
op/op mice and WT littermates for the presence of Aβ
plaques. Using 2 different polyclonal Aβ antibodies,
R1282 and DW14 [20] we did not detect Aβ deposition in
the CNS of either op/op or WT mice (Figure 5). Commer-
cially available polyclonal antibodies specific for Aβ40
and Aβ42 did not label plaques in op/op mice or wildtype
mice (Figure 6). In all cases we could detect Aβ in the CNS
of an APP transgenic mouse brain in the same staining run
and none was found when normal IgG was included as a
negative control. To confirm the immunohistochemical
data we also performed Thioflavin S and Congo red histo-
chemistry, both of which were negative in op/op and WT
mice. Therefore, based on this evidence we conclude that
Aβ is not deposited in op/op or WT mice.
To examine dopaminergic neurons we performed immu-
nohistochemistry using an antibody specific for tyrosine
hydroxylase (TH). Normal numbers and morphology of
TH positive neurons were found in the SN of both op/op
and WT mice at 30 days, 60 days and 7 months of age (Fig-
ure 4).
4. Discussion
The role of microglia and astrocytes in the inflammatory
cascade during neurodegenerative diseases is becoming
better delineated and may be a therapeutic target. How-
ever, the exact contribution of each glia cell type is diffi-
cult to determine in vivo due to the extensive
communication between astrocytes and microglia. In
addition, both types of glia can produce an overlapping
array of cytokines, chemokines and other molecules dur-
ing an inflammatory response [2]. It has been reported 
Quantification of CD11b expression in the hippocampus and  substantia nigra Figure 2
Quantification of CD11b expression in the hippocampus 
and substantia nigra. Computer assisted quantification of 
CD11b immunoreactivity demonstrated a significant difference in 
the hippocampus between WT (n = 3) and op/op (n = 3) mice at 
30 days of age. This was also seen in the substantia nigra. Note the 
lower values in the substantia nigra compared to the hippocampus 
in both WT and op/op mice. All values are expressed as mean ± 
SEM and statistical significance was determined using the Mann 
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CD45 and MHC II immunoreactivity in op/op and wildtype mice Figure 3
CD45 and MHC II immunoreactivity in op/op and wildtype mice. CD45 immunoreactivity is reduced in the hippocampus of op/
op mice (A) as compared to age matched wildtype mice (B). Only larger round cells located near blood vessels were labeled in the op/op 
mice, whilst in wildtype mice ramified microglia can be found. In both op/op (C) and wildtype (D) mice MHC II immunoreactive cells were 
found solely in the choroid plexus, while the overlying hippocampus was devoid of labeled cells. scale bar – 100 μm.
CD200 immunoreactivity is similar between WT and op/op mice Figure 4
CD200 immunoreactivity is similar between WT and op/op mice. Photomicrographs demonstrate CD200 expression in the hip-
pocampus of both WT (A) and op/op mice (B) at 30 days of age. There is wide spread staining found throughout the neuropil of the hip-
pocampus except the CA regions and dentate gyrus. There was less CD200 immunoreactivity in the substantia nigra of both WT (C) and 
op/op mice (D). CA1- field CA1 of hippocampus, CC- corpus callosum, DG- dentate gyrus, SNR- substantia nigra, reticular, SNC- sub-
stantia nigra, compact Scale bar – 100 μm.Journal of Neuroinflammation 2007, 4:31 http://www.jneuroinflammation.com/content/4/1/31
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Aβ plaques were not detected but tyrosine hydroxylase positive neurons were present in op/op mice Figure 5
Aβ plaques were not detected but tyrosine hydroxylase positive neurons were present in op/op mice. The rabbit polyclonal 
anti-Aβ antibody, DW14, did not detect Aβ deposition in WT (A) or op/op mice (B) in the hippocampus or overlying cortex of 30 day-
old mice. A cryosection from a 12 month-old APP-tg mouse (C) was included in the same immunohistochemistry experiment as a posi-
tive control and shows abundant Aβ plaques. Tyrosine hydroxylase (TH) was used to immunolabel dopaminergic neurons in the substan-
tia nigra. There were comparable numbers of TH expressing neurons in WT (D) and op/op (E) mice. The morphology of the 
dopaminergic neurons was similar in both groups of 30 day-old mice. An adjacent section was incubated with normal rabbit IgG as a neg-
ative control (F) for the TH immunostaining and shows no labeled cells. CA1- field CA1 of hippocampus, CC- corpus callosum, DG- den-
tate gyrus, SNC- substantia nigra, compact. Scale bar A-C – 250 μm Scale bar D-F – 100 μm.
Cryosections from 30 day old op/op, wildtype and 12 month old APP-tg mice were examined using commercially available pol- yclonal antibodies for Aβ40 and Aβ42 Figure 6
Cryosections from 30 day old op/op, wildtype and 12 month old APP-tg mice were examined using commercially available polyclonal anti-
bodies for Aβ40 and Aβ42. There was no Aβ40 immunoreactivity in op/op (A), wildtype (B) mice, whilst the APP-tg (C) mouse section 
showed some dense plaques. The Aβ42 specific antibody demonstrated a similar finding with op/op (D) and wildtype (E) mice having no 
plaques, whilst APP-tg (F) mice showed clear labeling of plaques. scale bar – 500 μm.Journal of Neuroinflammation 2007, 4:31 http://www.jneuroinflammation.com/content/4/1/31
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that op/op mice have reduced numbers of microglia [16],
thus these mice may allow us to examine whether reduced
numbers of microglia affect the progression of neurode-
generative diseases following crossbreeding to AD mouse
models or pharmacological induced disease, such as 1-
methyl-4-1,2,3,6-tetrahydropyridine (MPTP). However, it
has been unclear if op/op mice have normal dopaminer-
gic neuronal development or if they deposit Aβ plaques
under normal conditions. In addition, the activation sta-
tus of microglia in op/op mice is still unclear. Without this
basic data, the suitability of op/op mice as a model in neu-
rodegenerative diseases was unknown, for example if
there are deficiencies in dopaminergic neurons, op/op
mice would not make a good model for PD.
There is evidence to suggest that the number of microglia
in op/op mice may not be decreased compared to WT
mice [23,24], whilst other reports demonstrate a signifi-
cant reduction in microglia [16,25]. Our data supports the
latter reports, as 30 day-old op/op mice had significantly
reduced numbers of CD11b positive cells in both the hip-
pocampus and SN. In addition, a panel of microglia/mac-
rophage markers including FcγIII/II receptors (CD16/
CD32), CD68, CD45 and the scavenger receptor class A
(CD204), immunolabeled fewer cells in 30 day-old op/op
mice compared to age-matched WT littermates. This sug-
gests that the residual microglia in op/op mice are not
activated or expressing alternative membrane markers
compared to WT mice. There did appear to be population
of macrophages like cells expressing MHCII in the choroid
plexus of both op/op and wildtype mice. In both WT lit-
termates and op/op mice there were fewer microglia, as
measured by CD11b immunoreactivity, in the SN com-
pared to the hippocampus. This is in direct contrast to a
previous report demonstrating that the density of micro-
glia is greater in SN compared to hippocampus [26],
though there are numerous differences between this
report and the previous. Among these differences are the
age of the mice examined, antibodies used and the strain
of mice. Further studies are required to determine which
of these variables is responsible for the difference. How-
ever, from the present study we can conclude that micro-
glia are indeed reduced in 30 day old op/op mice.
There are extensive interconnections between neurons,
microglia and astrocytes to control the activation and
function of microglia [18]. Some of the mechanisms by
which neurons downregulate microglia include the pro-
duction of neurotrophins [27], CD200 [28] and CD22
[29]. Microglia express both CD45, the receptor for CD22
and the CD200 receptor. Absence of neuronal CD200
leads to an accelerated microglia response in both the
facial nerve transection model and experimental autoim-
mune encephalitis [28]. There was no difference in the
neuronal expression pattern of CD200 when op/op and
WT mice were compared, therefore it appears that the
lower number of microglia in op/op mice does not affect
the development of this key downregulatory glycoprotein.
It would be interesting to determine if this also applies to
other known downregulatory proteins and mechanisms.
However, we did note that CD200 immunoreactivity
appeared to be less intense in the SN compared to the hip-
pocampus. This may be one mechanism by which the SN
is more susceptible to LPS induced damage compared to
other CNS regions [30], as the local neurons may not be
able to control the activation of the microglia. This may
have implications for Parkinson's disease and other neu-
rodegenerative diseases. Further studies to better quantify
CD200 protein in discrete brain regions will be informa-
tive. Interestingly a recent report has demonstrated that
CD200 is decreased in the hippocampus of older rats sug-
gesting that this may be a mechanism by which microglia
activation control is not as tightly regulated as rats age
[31]. However, our current study demonstrates that the
absence of microglia and CSF-1 does not affect neuronal
expression of CD200.
Previous reports have demonstrated that 30 day-old op/
op mice deposit Aβ plaques in several regions of the CNS,
including the cerebral cortex, hippocampus and hypothal-
mus [32,33]. However, in the current study we did not
detect Aβ plaques using four different Aβ antibodies (both
polyclonal and monoclonal antibodies), Congo red or
Thioflavin S histochemistry in 30 day, 60 day and 7
month old op/op mice. A possibility for the discrepancy
may be a non-specific binding of the Aβ antibody used in
the previous study. The previous study used only a single
antibody, did not report the dilution used and did not
describe the results of appropriate positive and negative
controls. Therefore, based on our extensive and careful
examination of the brain of op/op mice we conclude that
op/op mice do not deposit Aβ under normal conditions
more so than WT mice.
There are a normal number of TH positive neurons, with
the appropriate morphology seen in 30 day-old op/op
mice as compared to WT littermates. It has been demon-
strated that an injection of LPS into the SN causes a loss of
TH expressing neurons, thus it is likely that op/op mice
with the lower number of microglia would be resistant to
this phenomenon. It has been demonstrated that mice
with lower numbers of microglia and increased numbers
of astrocytes in the SN are resistant to MPTP induced
dopaminergic neuron loss [34]. If this is the case then it
would be expected that op/op mice would be highly
resistant to dopaminergic cell loss following MPTP treat-
ment. The use of op/op mice would allow the in vivo
study of astrocytes in mouse models of PD without the
confounding presence of microglia.Journal of Neuroinflammation 2007, 4:31 http://www.jneuroinflammation.com/content/4/1/31
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5. Conclusion
In summary, we have confirmed that microglia are
reduced in 30 day-old op/op mice compared to WT litter-
mates but have normal levels of TH+ dopaminergic neu-
rons. Unlike previous reports, we did not detect Aβ
plaques in op/op mice up to 7 months of age. We detected
a similar distribution of CD200 in the brains of op/op and
WT controls, with lower levels of staining in the SN. Taken
together these data demonstrate that op/op mice may be
an important mouse model to study the role of glia in
neurological diseases by breeding to transgenic mouse
models of neurodegenerative diseases or pharmacological
induced disease.
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